|
US2013156759A1
|
|
Methods of treating dementia using a gm-csf antagonist
|
|
EP2764021A2
|
|
Generation of antibodies to an epitope of interest that contains a phosphomimetic amino acid
|
|
CN104254340A
|
|
Methods of treating hematological proliferative disorders by targeting epha3 expressed on aberrant vasculature in bone marrow
|
|
CA2836947A1
|
|
Anti-emr1 antibodies
|
|
AU2012202240A1
|
|
Methods of treating chronic inflammatory diseases using a GM-CSF antagonist
|
|
EP2582388A2
|
|
Detection of epha3 as a marker of the presence of a solid tumor
|
|
EP2553150A1
|
|
Generation of antibodies to an epitope of interest
|
|
AU2011235867A1
|
|
EphA3 antibodies for the treatment of multiple myeloma
|
|
WO2011087799A1
|
|
A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection
|
|
CN102666589A
|
|
Antibodies to epha3
|
|
NZ594950A
|
|
Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3
|
|
WO2010093814A1
|
|
Methods of treating dementia using a gm-csf antagonist
|
|
WO2010091189A1
|
|
Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
|
|
EP2282757A1
|
|
Neutralization of gm-csf for the treatment of heart failure
|
|
AU2009206082A1
|
|
Methods of treating bone-loss disorders using a GM-CSF antagonist
|
|
NZ586357A
|
|
Antibodies to the pcrv antigen of pseudomonas aeruginosa
|
|
AU2007323541A1
|
|
Methods of treating chronic inflammatory diseases using a GM-CSF antagonist
|
|
US2008171038A1
|
|
Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
|
|
CN101568647A
|
|
Secretion of antibodies without signal peptides from bacteria
|
|
EP2990053A1
|
|
Antibody specificity transfer using minimal essential binding determinants
|
